A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate pharmacodynamics, safety and pharmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.

Trial Profile

A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate pharmacodynamics, safety and pharmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs BI 1467335 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Mar 2018 Planned End Date changed from 9 Jul 2018 to 12 Apr 2019.
    • 26 Mar 2018 Planned primary completion date changed from 11 Jun 2018 to 15 Mar 2019.
    • 05 Sep 2017 Planned End Date changed from 15 May 2018 to 9 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top